Nodel' M R, Iakhno N N
Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):32-8.
The effect of the dopamine receptor antagonist mirapex on emotional disorders (anxiety, depression), cognitive disturbances and sleep disorders has been studied in 66 patients with Parkinson's disease. Mirapex has been administered in addition to levodopa and other antiparkinsonian drugs in dosage 3,5+/-1,1 mg daily to 36 patients with emotional and cognitive disorders and in dosage 2,9+/-0,96 mg daily to 30 patients with sleep disorders. Patient's state has been assessed using a number of psychometric scales and neuropsychological tests. The effectiveness of Mirapex in all disorders studied has been shown.
在66例帕金森病患者中研究了多巴胺受体拮抗剂米拉帕对情绪障碍（焦虑、抑郁）、认知障碍和睡眠障碍的影响。除左旋多巴和其他抗帕金森病药物外，还对36例有情绪和认知障碍的患者每日给予剂量为3.5±1.1毫克的米拉帕，对30例有睡眠障碍的患者每日给予剂量为2.9±0.96毫克的米拉帕。使用多种心理测量量表和神经心理学测试对患者的状态进行了评估。结果表明米拉帕对所有所研究的障碍均有效。
